Abstract
Sensitive and high-throughput molecular detection assays are essential for managing the COVID-19 pandemic. While nasopharyngeal swabs (NPS) are the standard specimen, they present challenges including patient discomfort and risks to healthcare workers. This study validates the QuantiVirus™ SARS-CoV-2 multiplex test for use with saliva specimens. The assay demonstrates a limit of detection (LOD) of 100–200 copies/mL and shows high clinical performance comparable to NPS-based testing. Furthermore, the study confirms the feasibility of saliva sample pooling (up to 6 samples), providing a scalable solution for population-wide screening.
Introduction
Since the emergence of SARS-CoV-2, molecular detection via real-time reverse transcription-polymerase chain reaction (RT-PCR) has been the primary diagnostic tool. Traditionally, these assays rely on nasopharyngeal swab (NPS) or oropharyngeal swab (OPS) specimens. However, the collection of these samples is invasive, often causing patients to cough or sneeze, which increases the risk of viral transmission to healthcare providers. This risk necessitates the heavy use of personal protective equipment (PPE) and specialized training for collection personnel.
Saliva has emerged as a promising alternative specimen. It can be self-collected, reducing the burden on healthcare infrastructure and improving patient compliance. This paper evaluates the performance of the QuantiVirus™ SARS-CoV-2 multiplex test, focusing on its sensitivity, clinical agreement with NPS, and its application in high-throughput pooled testing environments.
Methodology
The QuantiVirus™ Multiplex Assay
The QuantiVirus™ SARS-CoV-2 Multiplex Test is designed as a real-time RT-qPCR assay targeting three distinct regions of the viral genome: the Orf1ab, N, and E genes. This redundancy is critical for maintaining diagnostic accuracy even as the virus undergoes mutations. Additionally, the assay includes a human RNase P internal control to verify sample integrity and the success of the nucleic acid extraction process.
High-Throughput Automation and Platform Compatibility
To address the need for large-scale testing, the assay was integrated with the MGI MGISP-960 automated workstation, which can process 192 samples in approximately 80 minutes. Validation was conducted across four major qPCR platforms to ensure broad laboratory utility:
- Applied Biosystems 7500 Fast Dx
- Bio-Rad CFX384
- Roche LightCycler 480 II
- Thermo Fisher QuantStudio 5
Clinical and Community Samples
The study utilized a diverse range of samples for validation:
- Reference Materials: SeraCare Accuplex SARS-CoV-2 reference panels were used to determine the Limit of Detection (LOD).
- Clinical NPS Samples: 85 known positive and 90 known negative samples (previously characterized by the Abbott m2000 system).
- Paired Specimens: 20 sets of matched NPS and saliva samples from recovering COVID-19 patients.
- Community Screening: 389 saliva samples collected from asymptomatic individuals in California.
Key Insights and Results
Overcoming Saliva Viscosity
A significant technical hurdle in saliva testing is the specimen's viscosity, which can interfere with automated pipetting. The researchers addressed this by using a collection kit containing Viral Transport Media (VTM) to dilute the saliva by 50% immediately upon collection. This step stabilized the viral RNA and ensured the sample was compatible with high-throughput liquid handling systems.
Analytical Sensitivity and Specificity
The LOD for the QuantiVirus™ test was confirmed at 100–200 copies/mL, indicating high sensitivity. In clinical evaluations using NPS samples, the test achieved a Positive Percentage Agreement (PPA) of 100% and a Negative Percentage Agreement (NPA) of 98.9%. Cross-reactivity testing against a panel of common respiratory pathogens (including MERS-CoV and various Influenza strains) showed no false positives, confirming high specificity.
Saliva vs. NPS Performance
In the comparison of 20 paired samples, the QuantiVirus™ test showed an 80% concordance rate between saliva and NPS. Notably, the QuantiVirus™ assay detected the virus in three patients that the Abbott m2000 assay missed, suggesting that the lower LOD of the QuantiVirus™ test provides a sensitivity advantage in patients with low viral loads.
Feasibility of Sample Pooling
Pooling samples is a vital strategy for conserving reagents and increasing throughput during periods of high demand. The study evaluated 1:6 and 1:12 pooling ratios:
- 6-Sample Pooling: Maintained a sensitivity of 94.8% and a specificity of 100%.
- 12-Sample Pooling: Resulted in a drop in the Negative Predictive Value (NPV) to 80%.
These results suggest that a 6-sample pooling strategy is a highly effective "sweet spot" for maintaining diagnostic integrity while significantly expanding testing capacity.
Discussion and Conclusion
The findings demonstrate that saliva is a reliable and effective specimen for SARS-CoV-2 detection. The QuantiVirus™ multiplex test provides the sensitivity required to detect low viral titers, which is essential for identifying asymptomatic carriers in community screening. While the study noted an 80% concordance between saliva and NPS in recovering patients, the differences likely stem from the biological distribution of the virus at different stages of infection rather than assay failure.
In conclusion, the QuantiVirus™ SARS-CoV-2 multiplex test, combined with saliva collection and automated processing, offers a patient-friendly, high-throughput, and sensitive solution for large-scale COVID-19 surveillance. The feasibility of 6-sample pooling further enhances its utility for monitoring populations and managing the ongoing public health challenge.
Summary updated